- Home
- IDE vs IPHA Comparison
IDE vs IPHA Comparison
Compare IDE & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDE
- IPHA
- Stock Information
- Founded
- IDE 2010
- IPHA 1999
- Country
- IDE United States
- IPHA France
- Employees
- IDE N/A
- IPHA N/A
- Industry
- IDE Finance/Investors Services
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- IDE Finance
- IPHA Health Care
- Exchange
- IDE Nasdaq
- IPHA Nasdaq
- Market Cap
- IDE 176.9M
- IPHA 148.1M
- IPO Year
- IDE N/A
- IPHA 2019
- Fundamental
- Price
- IDE $11.66
- IPHA $1.84
- Analyst Decision
- IDE
- IPHA Strong Buy
- Analyst Count
- IDE 0
- IPHA 1
- Target Price
- IDE N/A
- IPHA $11.50
- AVG Volume (30 Days)
- IDE 33.5K
- IPHA 9.8K
- Earning Date
- IDE 01-01-0001
- IPHA 09-12-2024
- Dividend Yield
- IDE 8.83%
- IPHA N/A
- EPS Growth
- IDE N/A
- IPHA N/A
- EPS
- IDE N/A
- IPHA N/A
- Revenue
- IDE N/A
- IPHA $36,202,722.00
- Revenue This Year
- IDE N/A
- IPHA N/A
- Revenue Next Year
- IDE N/A
- IPHA $102.87
- P/E Ratio
- IDE N/A
- IPHA N/A
- Revenue Growth
- IDE N/A
- IPHA N/A
- 52 Week Low
- IDE $8.61
- IPHA $1.57
- 52 Week High
- IDE $10.46
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- IDE 60.78
- IPHA 44.62
- Support Level
- IDE $11.40
- IPHA $1.73
- Resistance Level
- IDE $11.72
- IPHA $2.06
- Average True Range (ATR)
- IDE 0.15
- IPHA 0.11
- MACD
- IDE -0.02
- IPHA 0.01
- Stochastic Oscillator
- IDE 70.27
- IPHA 55.37
About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest
Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.